Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829662 | 0.98 | LMNA (0.38) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL873892 | 0.98 | LMNA (0.38) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Alcohol SCHEMBL15066415 | 0.95 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL8325036 | 0.93 | LMNA (0.34) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL6573573 | 0.93 | LMNA (0.34) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Fructose SCHEMBL11151878 | 0.88 | CYP2C9 (0.34) | LMNAL3MBTL1PDE4A | |
| SCHEMBL18341352 | 0.86 | AKR1B1 (0.33) | — | |
| SCHEMBL17844291 | 0.86 | — | — | |
| SCHEMBL2722434 | 0.85 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL4271266 | 0.85 | LMNA (0.35) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139969-A | Method for rapid infiltration of 3D scaffolds with cells | 紫露草公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2010049783-A1 | STEM CELLS IN OBSTETRICS AND GYNAECOLOGY | PATKI RESEARCH FOUNDATION & HOSPITAL (IN) | 2010-05-06 | — | — | WO | disclosed |
| US-20080305074-A1 | Stem cell factor | AMGEN INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070071714-A1 | Stem cell factor | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-7144731-B2 | SCF antibody compositions and methods of using the same | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050261175-A1 | SCF antibody compositions and methods of using the same | BIOVITRUM AB (PUBL) (SE) | 2005-11-24 | — | — | US | disclosed |
| US-6967029-B1 | Method for increasing hematopoietic progenitor cells by stem cell factor | AMGEN INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050080250-A1 | Methods of stimulating growth of stromal cells in a human | ZSEBO KRISZTINA M (US) | 2005-04-14 | — | — | US | disclosed |
| US-6852313-B1 | Method of stimulating growth of melanocyte cells by administering stem cell factor | AMGEN INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6841147-B2 | Stem cell factor compositions | AMGEN, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040181044-A1 | Method of stimulating growth of epithelial cells by administering stem cell factor | ZSEBO KRISZTINA M (US) | 2004-09-16 | — | — | US | disclosed |
| US-6759215-B1 | FOR TREATING DISORDERS INVOLVING HEMATOPOIETIC CELLS | AMGEN INC. | 2004-07-06 | — | — | US | disclosed |
| US-20020031491-A1 | STEM CELL FACTOR: COMPOSITION CLAIMS | BIOVITRUM AB (PUBL) (SE) | 2002-03-14 | — | — | US | disclosed |
| US-20020018763-A1 | A METHOD OF STIMULATING GROWTH OF STROMAL CELLS WITH STEM CELL FACTOR (SCF) POLYPEPTIDES | ZSEBO KRISZKINA M (US) | 2002-02-14 | — | — | US | disclosed |
| US-6248319-B1 | BLOOD DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2001-06-19 | — | — | US | disclosed |
| US-6218148-B1 | DNA SEQUENCE OF PROTEIN; RECOMBINANT CULTURE PRODUCTION; REGENERATION OF HEMATOPOIETIC SYSTEM AFTER CHEMOTHERAPY, RADIATION, BLOOD DISORDERS, OR VIRAL DISORDERS SUCH AS ACQUIRED IMMUNE DEFICIENCY SYNDROME | AMGEN INC. | 2001-04-17 | — | — | US | disclosed |
| US-6207417-B1 | NUCLEOTIDE SEQUENCES FOR THE EXPRESSION OF EXOGENOUS GENES; FOR THE TREATMENT OF BLOOD DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2001-03-27 | — | — | US | disclosed |
| US-6207454-B1 | EXPOSING TARGET MAMMALIAN CELL THAT EXPRESSES STEM CELL FACTOR RECEPTOR TO ACTIVE STEM CELL FACTOR OR ANALOG, THEN INTRODUCING POLYNUCLEOTIDE TO CELL; GENE THERAPY | AMGEN INC. | 2001-03-27 | — | — | US | disclosed |
| US-6207802-B1 | NON-HUMAN, MAMMALIAN POLYPEPTIDE OF DEFINED AMINO ACID SEQUENCE WHICH ACTIVATES THE GROWTH OF EARLY HEMATOPOIETIC PROGENITOR CELLS; TREATMENT OF BLOOD DISORDERS; ANTICARCINOGENIC AGENTS; BONE MARROW REGENERATION | AMGEN INC. | 2001-03-27 | — | — | US | disclosed |
| US-6204363-B1 | POLYPEPTIDE ASSOCIATED WITH CELL PROPAGATION; FOR THE TREATMENT OF CELL PROPAGATION DEFECTS IN CELLS | AMGEN INC. | 2001-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305074-A1 | Stem cell factor | KIT, CBFB, ILF2 | LMNA 3723/4885L3MBTL1 1324/4885PDE4A 2273/4885 |
| US-20020031491-A1 | STEM CELL FACTOR: COMPOSITION CLAIMS | CBFB, KIT, RUNX1 | LMNA 2923/4885L3MBTL1 2527/4885PDE4A 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.